The combination of orlistat, lonidamine and 6‑diazo‑5‑oxo‑L‑norleucine induces a quiescent energetic phenotype and limits substrate flexibility in colon cancer cells
Structure of 6-diazo-5-oxo-norleucine-bound human gamma-glutamyl transpeptidase 1, a novel mechanism of inactivation
Model studies towards prodrugs of the glutamine antagonist 6-diazo-5-oxo-l- norleucine (DON) containing a diazo precursor - ScienceDirect
Tumor-Targeted Delivery of 6-Diazo-5-oxo-l-norleucine (DON) Using Substituted Acetylated Lysine Prodrugs | Journal of Medicinal Chemistry
Protective Effects of Glutamine Antagonist 6-Diazo-5-Oxo-l-Norleucine in Mice with Alphavirus Encephalomyelitis | Journal of Virology
Discovery of 6-Diazo-5-oxo-l-norleucine (DON) Prodrugs with Enhanced CSF Delivery in Monkeys: A Potential Treatment for Glioblastoma | Journal of Medicinal Chemistry
GMP Synthase Is Required for Virulence Factor Production and Infection by Cryptococcus neoformans*
Chemical reactivity of 6-diazo-5-oxo-l-norleucine (DON) catalyzed by metalloporphyrins (Fe,Ru) - ScienceDirect
WO2016112386A1 - Methods for bioanalysis of 6-diazo-5-oxo-l-norleucine (don) and other glutamine antagonists - Google Patents
6-Diazo-5-oxo-L-norleucine | CAS 157-03-9 | SCBT - Santa Cruz Biotechnology